SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals

被引：0

作者：

Kelin She

Shenghua Fang

Wei Du

Xingxing Fan

Jiaxi He

Hui Pan

Liyan Huang

Ping He

Jun Huang

机构：

[1] The First Affiliated Hospital of Guangzhou Medical University,Department of Thoracic Surgery

[2] Guangzhou Research Institute of Respiratory Disease,Department of Thoracic Surgery

[3] China Key Laboratory of Respiratory Disease,Department of Pathology

[4] National Center for Clinical Trials on Respiratory Diseases,undefined

[5] The Central Hospital of Shaoyang City,undefined

[6] Affiliated Cancer Hospital & Institute of Guangzhou Medical University,undefined

[7] Dongguan People’s Hospital,undefined

[8] State Key Laboratory of Quality Research in Chinese Medicine,undefined

[9] Macau Institute for Applied Research in Medicine and Health,undefined

[10] Macau University of Science and Technology,undefined

[11] The First Affiliated Hospital of Guangzhou Medical University,undefined

来源：

Cancer Cell International | / 19卷

关键词：

SCD1; EGFR; AKT; EMT; Lung cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance
Chang, Kwang-Yu
Tsai, Shan-Yin
Chen, Shang-Hung
Tsou, Hsiao-Hui
Yen, Chia-Jui
Liu, Ko-Jiunn
Fang, Hsun-Lang
Wu, Hung-Chang
Chuang, Bin-Fay
Chou, Shao-Wen
Tang, Careen K.
Liu, Shyun-Yeu
Lu, Pei-Jung
Yen, Ching-Yu
Chang, Jang-Yang
JOURNAL OF BIOMEDICAL SCIENCE, 2013, 20
[42] Drug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C.
Sellers, W. R.
ONCOGENE, 2008, 27 (41) : 5511 - 5526
[43] MiR-1299 Impedes the Progression of Non-Small-Cell Lung Cancer Through EGFR/PI3K/AKT Signaling Pathway
Cao, Shengya
Li, Longfei
Li, Jia
Zhao, Hongying
ONCOTARGETS AND THERAPY, 2020, 13 : 7493 - 7502
[44] MiR-32 Suppresses the Development of Lung Cancer via Modulating PI3K/Akt
Liu, Qing-Feng
Zhang, Ye
Deng, Lei
Zhang, Tao
Xiao, Jian-Ping
Zhou, Zong-Mei
Bi, Nan
JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2021, 11 (07) : 1271 - 2021
[45] ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways
Liu, Xin-Li
Zhang, Xu-Tao
Meng, Jin
Zhang, Hong-Fei
Zhao, Yong
Li, Chen
Sun, Yang
Mei, Qi-Bing
Zhang, Feng
Zhang, Tao
ONCOTARGET, 2017, 8 (33) : 54265 - 54276
[46] TGF-β1 promotes SCD1 expression via the PI3K-Akt-mTOR-SREBP1 signaling pathway in lung fibroblasts
Zhou, Zili
Liang, Shixiu
Zhou, Zicong
Liu, Jieyi
Zhang, Jinming
Meng, Xiaojing
Zou, Fei
Zhao, Haijin
Yu, Changhui
Cai, Shaoxi
RESPIRATORY RESEARCH, 2023, 24 (01)
[47] Halofuginone Sensitizes Lung Cancer Organoids to Cisplatin via Suppressing PI3K/AKT and MAPK Signaling Pathways
Li, Hefei
Zhang, Yushan
Lan, Xiaomei
Yu, Jianhua
Yang, Changshuang
Sun, Zhijian
Kang, Ping
Han, Yi
Yu, Daping
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
[48] Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
Zhao, Zhong-Quan
Yu, Zhong-Yang
Li, Jie
Ouyang, Xue-Nong
ONCOLOGY LETTERS, 2016, 12 (01) : 63 - 68
[49] CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis
Wan, Zongmiao
Huang, Sheng
Mo, Fengbo
Yao, Yao
Liu, Gangan
Han, Zhimin
Chen, Ming
Li Zhiyun
EXPERIMENTAL CELL RESEARCH, 2019, 384 (02)
[50] TGF-β1 promotes SCD1 expression via the PI3K-Akt-mTOR-SREBP1 signaling pathway in lung fibroblasts
Zili Zhou
Shixiu Liang
Zicong Zhou
Jieyi Liu
Jinming Zhang
Xiaojing Meng
Fei Zou
Haijin Zhao
Changhui Yu
Shaoxi Cai
Respiratory Research, 24

← 1 2 3 4 5 →